ArticleCell death & disease2026
UPR/ATF4/Noxa pathway overactivation through SERCA2 inhibition or ONC201 treatment combined with ABT-737 triggers apoptosis in chemoresistant ovarian cancer cells and patient-derived tumor organoids.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Ovarian cancer has a poor clinical prognosis due to chemoresistance following carboplatin/paclitaxel treatment. This phenomenon can be explained by an imbalanced ratio of [anti-apoptotic (BCL-xL/MCL-1)] to [pro-apoptotic (Noxa, BIM, PUMA)] BCL-2 family members that prevents apoptosis initiation. Consequently, any treatment capable of counterbalancing this ratio could be beneficial in the management of ovarian cancer. Calcium signaling is strongly implicated in resistance to apoptosis, as it depends on, but also regulates, the expression of the ratio of BCL-2 family members, making calcium-targeted strategies relevant to overcoming chemoresistance. Knowing that SERCA2 calcium pumps regulation plays a major role in controlling the ER stress-induced UPR response that could lead to pro-apoptotic protein upregulation and cell death, we therefore evaluated whether their inhibition could elicit apoptosis or sensitize ovarian cancer cells to other therapeutic strategies. For this purpose, the platinum-resistant cell line, OAW42-R, was treated with anti-SERCA2 strategies which revert the BCL-2 family member expression ratio in favor of pro-apoptotic proteins. Combination with the BH3-mimetic ABT-737 exacerbates this imbalance not only by inhibiting BCL-xL activity but also through over-induction of the UPR/ATF4/Noxa axis, leading to MCL-1 inhibition. This dual effect of ABT-737 upon ER stress fully suppresses the anti-apoptotic capacities of cancer cells, leading to massive mitochondrial apoptosis. This point was supported with ONC201, the first member of the imipridone family of anticancer drugs to enter the clinic, whose ability to trigger UPR/ATF4/Noxa led to apoptosis commitment when it was combined with ABT-737 treatment. The therapeutic efficacy of these combinations was also proved in patient-derived tumor organoid models (PDTO), leading to their structural disintegration and reduced viability. Collectively, our study highlights that ABT-737, through BCL-xL inhibition and synergy with ER stress inducers, triggers ovarian cancer death, offering promising strategies for overcoming chemoresistance in relapsed ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.